The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis

Myelofibrosis (MF) patients can present with a wide spectrum of disease characteristics. We analysed the consistency of ruxolitinib efficacy across patient subgroups in the COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment (COMFORT-I,) a double-blind trial, where patients with interme...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Levy, Richard S., Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael, Miller, Carole, Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth, Lyons, Roger M., Paquette, Ronald, Raza, Azra, Vaddi, Kris, Erickson-Viitanen, Susan, Sun, William, Sandor, Victor, Kantarjian, Hagop M.
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4055021/
https://ncbi.nlm.nih.gov/pubmed/23480528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12274
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires